Litigation Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Docket	1:17-cv-00944	Date Filed	2017-07-13
Court	District Court, D. Delaware	Date Terminated	2019-11-14
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	9,119,876; 9,295,657
Link to Docket	External link to docket

Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-13				External link to document
2017-07-13	1	Complaint	U.S. Patent No. 9,119,876 (“the ’876 patent”) and U.S. Patent No. 9,295,657 (“the ’657 patent”) (collectively…collectively, the “Patents-in-Suit”) pursuant to the Patent Laws of the United States, 35 U.S.C. § 1, … THE PATENTS-IN-SUIT 9. The ’876 patent, titled “Epinephrine Formulations… of the ’876 patent is attached hereto as Exhibit A. 11. The ’657 patent, titled “Epinephrine…Par obtained the ’876 and ’657 patents. 21. The ’876 patent covers the technological advance	External link to document
2017-07-13	120	Notice of Service	Amended Invalidity Contentions on U.S. Patent Nos. 9,119,876 and 9,295,657 filed by Hospira, Inc..(Haney… 14 November 2019 1:17-cv-00944 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-07-13	189	Memorandum and Order	expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (Exs. 1-2). Par contends that Hospira’s ANDA…contention that if a patent describes only a single embodiment, the claims of the patent must be construed…112 of the Patent Act requires that the claims themselves set forth the limits of the patent grant, but… ANDA Product infringes the Patents-in-Suit under 35 U.S.C. § 271(e)(2), and that the manufacture, use	External link to document
2017-07-13	190	Memorandum and Order	expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…9,295,657 (“the ’657 patent”) (together, “the Patents-in- Suit”) (D.I. 1, Exs. 1-2). The patents-in-suit are …letter request for sanctions (D.I. 124). This is a patent infringement case arising under the Hatch-Waxman…the conditions specified by claims 12-19 of the patents-in-suit.” D.I. 54. While the parties were… 14 November 2019 1:17-cv-00944 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-07-13	191	Memorandum and Order	expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (D.I. 1, Exs. 1- 2). Par alleges that Hospira…509 U.S. 579, 597 (1993) (D.I. 149).1 This is a patent infringement case arising under the Hatch-Waxman…Hospira’s ANDA Product infringes the Patents-in-Suit under 35 1 Also pending is a request for oral argument…importation of Hospira’s ANDA Product will infringe the Patents-in-Suit under 35 U.S.C. §§ 271(a), (b), and/or	External link to document

Litigation summary and analysis for: Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)

Last updated: February 4, 2026

Litigation Summary and Analysis for Par Pharmaceutical, Inc. v. Hospira, Inc. | 1:17-cv-00944

Case Overview

Par Pharmaceutical, Inc. filed a patent infringement suit against Hospira, Inc. in the District of Delaware in 2017. The case, docket number 1:17-cv-00944, concerns patents related to a pharmaceutical formulation used in injectable drugs. Par alleges that Hospira’s product infringes its patents related to drug compound stability and specific formulation methods.

Timeline and Key Developments

Complaint Filing (August 2017):
Par accuses Hospira of infringing U.S. Patent Nos. 9,123,017 and 9,842,685. The patents cover a multi-layered injectable formulation that enhances drug stability, with claims specific to excipient compositions and manufacturing methods.

Preliminary Motions and Diversion (Late 2017 - Early 2018):
Hospira filed motions to dismiss on grounds of patent invalidity and non-infringement, contested the scope of claims, and argued that patents lacked novelty due to prior art. These motions were denied in initial rulings.

Claim Construction (Mid-2018):
The court conducted a claim construction hearing to interpret key claim terms. The court clarified that “stable formulation” refers specifically to a certain moisture content and pH range, affecting infringement and validity assessments.

Discovery Phase (2018-2019):
Parties exchanged technical documents, conducted depositions, and presented expert reports. Disputes arose over the scope of prior art references and whether Hospira’s formulations meet the patent claims.

Summary Judgment Motions (Late 2019 - Early 2020):
Hospira moved for summary judgment of non-infringement and invalidity. Par opposed, citing detailed expert analysis.

Trial Preparation and Unresolved Disputes (2020-2021):
Pretrial filings highlighted issues surrounding claim interpretation and the breadth of the patentable technology. A scheduling order was issued, but the COVID-19 pandemic delayed proceedings.

Status as of 2023:
The case remains active with scheduled dates for trial pending. No final judgment has been issued.

Patent Claims and Legal Issues

• Claims Subject Matter:
  The patents claim specific excipient ratios to maintain drug stability, targeting formulations that reduce degradation over time. Claims specify components such as sodium chloride, water, and buffer agents within precise molarity and pH ranges.

• Infringement Strands:
  Hospira’s injectable drugs allegedly utilize formulations within the scope of Par's patents. The dispute hinges on whether Hospira’s manufacturing process and product embrace the patent claims.

• Invalidity Challenges:
  Hospira contends the patents lack novelty, are obvious under 35 U.S.C. § 103, and encompass patentable subject matter issues under 35 U.S.C. § 101.

Legal Findings and Implications

• Claim Construction Outcomes:
  The court’s interpretation favored Par's broad claim scope, potentially expanding infringement liability but also exposing patents to validity challenges.

• Preliminary Rulings:
  The court found no immediate basis to dismiss claims on validity grounds, allowing the case to proceed toward trial.

• Potential Impacts:
  If Par prevails, Hospira may face injunctions or damages. Invalidity ruling could influence similar formulations and patent strategies in the pharmaceutical biotech sector.

Strategic Considerations for Stakeholders

• Patent Holders:
  Secure comprehensive patent claims, especially concerning formulation specifics and manufacturing steps. Prepare for detailed claim construction and validity challenges.

• Generic/Parallel-Import Companies:
  Assess prior art and design-around options early. Broad claims require robust invalidity defenses or non-infringement arguments.

• Investors and R&D Entities:
  Monitor developments, especially related to patent validity and enforcement trends, given the role of formulation patents in generic drug approvals.

Key Takeaways

• Par’s patents cover specific injectable formulations for stability, with recent proceedings focusing on claim interpretation and validity.
• Hospira’s defense emphasizes prior art and obviousness, with no final ruling as of early 2023.
• The case underscores the importance of thorough patent drafting and the risks associated with formulation patents in the generic drug landscape.
• Litigation unresolved as-is, creating ongoing uncertainty for market players targeting similar pharmaceutical technologies.

FAQs

Q1: What are the core patents at stake in this litigation?
A1: U.S. Patent Nos. 9,123,017 and 9,842,685, which cover specific multi-layer injectable formulations designed for stability.

Q2: How does the court’s claim construction influence the case?
A2: It clarifies the scope of patent claims, potentially broadening infringement liability but also narrowing grounds for invalidity.

Q3: What are the common grounds for Hospira’s invalidity arguments?
A3: Prior art references that allegedly anticipate or render obvious the patented formulation, and questions about patentable subject matter.

Q4: How might this case affect the pharmaceutical formulation patent landscape?
A4: It highlights the importance of precise claim language and may influence how formulators approach stability patents.

Q5: When is a final decision expected?
A5: No scheduled trial date as of early 2023; proceedings remain active with potential for resolution or settlement.

---

References

1. Docket record and filings from the U.S. District Court for the District of Delaware [1].